Medipron Holds Multiple Patents for New Drug with Same Mechanism as FDA-Approved Alzheimer’s Treatment Leqembi, Signaling Positive Prospects

Medipron announced that it holds numerous patents targeting the same mechanism as the Alzheimer's treatment drug 'Lequembi (active ingredient: lecanemab),' which has been approved by the U.S. Food and Drug Administration (FDA).

On the 10th, a Medipron representative stated, "We warmly welcome the FDA approval of Lequembi, a new drug jointly developed by Biogen and Eisai," adding, "The approval of this treatment confirms that the beta-amyloid mechanism is a very important target in Alzheimer's treatment, which is the same target as the patented new drug substances for dementia treatment held by Medipron."

Medipron holds over 50 domestic and international patents for new drug substances targeting the beta-amyloid mechanism. Representative new drug substances for dementia treatment include OGA inhibitors, which obtained domestic patents this year, as well as beta-amyloid inhibitors, RAGE inhibitors, and glutaminyl cyclase inhibitors.

Director Lim explained, "Non-clinical trials for the OGA inhibitor, which obtained domestic patents this year, are being prepared. The OGA inhibitor has experimentally confirmed a reduction in dementia markers through inhibition of beta-amyloid and tau," adding, "The newly developed dementia treatment substance that suppresses brain inflammation (NLRP3 inhibitor) has demonstrated efficacy in gene-modified mice, and patent acquisition and non-clinical trials are also underway."

He continued, "Based on this, as a leading Korean company developing dementia treatments, we will strive to ensure that K-dementia treatments succeed in the global dementia treatment market."

This content was produced with the assistance of AI translation services.